Corvus Pharmaceuticals, Inc. (CRVS) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 12 Buy, 1 Hold.
The consensus price target is $31.80 (low: $27.00, high: $42.00), representing an upside of 110.5% from the current price $15.11.
Analysts estimate Earnings Per Share (EPS) of $-0.92 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.02 vs est $-0.92 (missed -10.7%). 2025: actual $-0.19 vs est $-0.25 (beat +22.4%). Analyst accuracy: 81%.
CRVS Stock — 12-Month Price Forecast
$31.80
▲ +110.46% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Corvus Pharmaceuticals, Inc., the average price target is $31.80, with a high forecast of $42.00, and a low forecast of $27.00.
The average price target represents a +110.46% change from the last price of $15.11.
Highest Price Target
$42.00
Average Price Target
$31.80
Lowest Price Target
$27.00
CRVS Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Corvus Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — CRVS
81%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.02
vs Est –$0.92
▼ 9.6% off
2025
Actual –$0.19
vs Est –$0.25
▲ 28.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CRVS
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
